Madrigal Pharmaceuticals inked an exclusive global licensing agreement worth over $2 billion to develop CSPC Pharmaceutical’s preclinical oral GLP-1 receptor agonist SYH-2086. The partnership aims to combine the asset with Madrigal’s MASH drug Rezdiffra to enhance treatment for metabolic-associated steatotic liver disease. Development is expected to commence early next year, signaling Madrigal’s strategic expansion beyond fibrosis toward metabolic disease therapeutics.